BioSpace News Archive

Rite Aid Corporation announced that it has commenced cash tender offers to purchase up to $100 million aggregate principal amount of its outstanding 7.70% Senior Notes due 2027 and 6.875% Senior Notes due 2028 The Tender Offers support the Company’s objective to reduce its total indebtedness while managing its liquidity and interest expense.

SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of veteran commercial executive Diane Parks to its board of directors. Among her many achievements, Ms. Parks is credited with developing and executing the strategic plan for the launch of the novel CAR-T therapy Yescarta ® and the marketing strategies for the b

Dr. Bassan Joins BiomX as the company advances into the clinic.

BioSig Technologies, Inc. announced that the Company is opening a new technology development office at Discovery Square, a 16 block sub-district built in collaboration with Mayo Clinic in Rochester, Minnesota.

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces the appointment of Martina Molsbergen, Chief Executive Officer of C14 Consulting, to its Board of Directors, effective as of October 11, 2019.

Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced its sponsorship of the Fourth International Symposium on Sigma-2 Receptors: Role in Health and Disease.

Immutep Limited announces mature positive efficacy data from its TACTI-mel Phase I clinical study combining its lead product candidate, eftilagimod alpha with KEYTRUDA® in metastatic melanoma.

Heska Corporation, a provider of advanced veterinary diagnostic and specialty products, plans to report its third quarter 2019 financial performance in a press release on Tuesday, November 5, 2019 before the market opens, and to host an earnings call to discuss the results at 9 a.m. MT / 11 a.m. ET on the same day..

Journal Reports OTL38 Reveals Undetected Cancer in 48% of Patients

Findings show that REL-1017 has rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures